Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has been making waves in the Biotechnology industry with its focus on developing and commercializing treatments for orphan dermatologic diseases. Despite the company's recent loss, market volatility
has created a unique investment opportunity that savvy investors should not overlook. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders. This promising development has the potential to significantly increase the company's market value, currently standing at $3.03 billion.